http://www.oxford-instruments.com/Pages/home.aspx


Oxford Instruments is a leading provider of high technology tools and systems for research and industry. We design and manufacture equipment that can fabricate, analyse and manipulate matter at the atomic and molecular level.

Oxford Instruments has discrete business groups operating in three sectors. This means we can focus our expertise, our technologies and our innovation on offering our customers high quality products and service that meet their stringent requirements.







Financial Calendar


Half Year/Interim Results Announcement

Tuesday November 13th 2012 : 9.30am The London Stock Exchange

Annual General Meeting:

Tuesday 11th September 2012 : 2.30pm

Oxford Instruments plc, Tubney Woods, Abingdon, Oxon OX13 4QX

26 September 2012 Ordinary shares quoted ex-dividend
28 September 2012 Record date for final dividend
30 September 2012 DRIP date
25 October 2012 Payment of final dividend
March 2013 Ordinary shares quoted ex-dividend
Dividend reinvestment (DRIP) last date for election
Record date for interim dividend
31 March 2013 Financial Year End

Oxford Instruments has stormed up more than 60% over the past 12 months, and reached a new year's high of 1,340p today. The company, which makes a variety of high-tech electronic tools for various sectors of industry, recorded a 48% rise in earnings per share (eps) in its full year to March, and July's interim update told us that sales and profits for the first quarter were ahead of last year.

Forecasts for the full year suggest a 10% rise in eps, though the dividend isn't worth talking about yet. On a P/E of nearly 20, this is clearly priced as a growth share.

Oxford Instruments plc Chairman's AGM Statement 2012



http://www.moneyam.com/action/news/showArticle?id=4442544

Oxford Instruments slumped by 97p (7%) to 1,268p after issuing its AGM statement this morning. The firm, which makes high-technology tools and systems for industry and research, told us that its trading remains pretty much in line with expectations. But the markets clearly didn't like the additional comment that the firm is seeing "some softness" in its industrial markets.

The shares are still up more than 50% over the past 12 months, and on a forward price-to-earnings ratio of 20, they've clearly got a bit more growth priced into them. There is no meaningful dividend to speak of yet -- it's less than 1%.

There's a thread on the Traders board for OXIG, but interest has dried up so thanks for starting this one D/C.

Todays words not received well, but as you say they have had a VG. run.

Thanks Stan. Some of the threads get very dated . It should recover.

Oxford Instruments on track to meet expectations
10:08 am by Sergei Balashov Shares in Oxford Instruments fell this morning after the group revealed that there has been "some softness" in its industrial markets
Oxford Instruments (LON:OXIG) said trading remains in line with expectations, but reported that there has been "some softness" in its industrial markets.

The group, which provides high technology tools and systems for industry and research, told investors that it is set to achieve its targets of a 14 percent increase in revenues and a 14 percent return on sales by the end of the financial year 2013/14.

In the year to March 2012, the company’s sales climbed 29 percent split equally between organic growth and three bolt on acquisitions.

Return on sales also improved within its targets, climbing to 12.5 percent from 10.7 percent.

In the current year, the group’s nanotechnology tools business has made good progress, while the industrial division has continued to trade in line with expectations.

The service unit has performed well providing aftermarket service to the installed base of Oxford Instruments equipment.

However, the group reported that while order intake from its research markets remains good, there has been “some softness” in its industrial markets.

“Despite the ongoing uncertainties in global economies, we believe the diversity of our activities combined with our strong pipe-line of new products will continue to provide good growth opportunities for the group,” said chairman of Oxford Instruments Nigel Keen.

“The board anticipates that Oxford Instruments will continue to make progress in line with our expectations for the financial year.”

Shares in the group were changing hands at 1,296 pence at 10am, down five percent from Monday’s close.

A buy recommendation in this weeks IC - The mere mention of ''some softness'' in order intake from its industrial markets helped chop as much as 10 per cent off the company share price. In an otherwise innocuous update, Oxford confirmed good progress at its high-profit-margin nanotechnology tools and services division since the March year-end, and added that the industrial unit is trading in line with expectations,
keeping the company on track to hit full-year targets. At 1288 the shares are a buy.

http://www.thisismoney.co.uk/money/investing/article-2203796/MIDAS-UPDATE-Tool-maker-Oxford-Instruments-tipped-rises-588.html

Interesting movements today on these I notice. might have been something to do with witching hour though.

Nice 5% rise today, welcomed as they have slipped a bit recently.

25 October 2012
Payment of final dividend

13th November 2012 (9.30am)
Half Year/Interim Results Announcement, The London Stock Exchange

13 Nov gives us half year figures, the results themselves are likely to be largely as expected, guidance on future revenues and profits should be very encouraging. Back in Sept the £747 million cap reported stellar order intake from its nano research markets, alongside unsurprising softness across some of its industrial market customers. Industrial demand should improve as economies pick up. Analysts at broker Investec are championing the prospects for 'strong growth and successive earnings upgrades'. The broker expects 5% earnings per share (EPS) growth to 64.8p for the 12 months to March 2013, followed by a further 15% advance to74.3p
A buy in this weeks shares mag.

RNS Number : 9243Q

Oxford Instruments PLC

13 November 2012






Release Date: 7am Tuesday 13th November 2012



Oxford Instruments plc

Announcement of Half Year Results for 2012/13



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Half Year Results for the six months to 30 September 2012.



Highlights:

· Good progress in the first half, in line with meeting our 14 Cubed growth plan objectives

· Revenue up 7.4% to £170.8 million (2011: £159.1 million)

· Adjusted profit before tax* up 23.5% to £23.1 million (2011: £18.7 million)

· Adjusted EPS* up 20.2% to 33.9 pence (2011: 28.2 pence)

· Reported EPS up 25.1% to 20.9 pence (2011: 16.7 pence)

· Continued increase in global demand for nanotechnology tools

· Focused R&D programme continued to underpin organic growth

· New product pipeline remains strong

· Net cash of £37.1 million at period end (2011: £11.9 million)

· Interim dividend increased by 10.1% to 3.05 pence (2011: 2.77 pence)



*Adjusted numbers are stated to give a better understanding of the underlying business. Details of adjusting items can be found in Note 2.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said:



"We have delivered a strong result in the first half in line with our 14 Cubed objectives. We have a broad spread of geographies and technologies, exposure to markets with long term structural growth, a strong pipeline of new products and a focus on improving efficiency. These factors should help us to remain resilient against a backdrop of sustained global economic uncertainty. We are continuing our pursuit of acquisitions that have the potential to enhance shareholder value and add to our range of technical capabilities.



The Board remains confident in the continued growth prospects of Oxford Instruments and the Group's ability to deliver shareholder value."

Good results

They do look good DC don't they, But lets see what the market thinks as these has been on the slide leading up to these results.

Stan perhaps they will rebuild over the next few weeks. Again good set of results.

presentation -

Interim Results Announcement 2012/13

http://www.oxford-instruments.com/OxfordInstruments/media/global/investors/half-year-results-documents/2012/Oxford-Instruments-plc-Half-Year-Results-Presentation-November-13-2012.pdf

Oxford Instruments: Liberum Capital raises target price from 1445p to 1515p, buy rating kept

A buy in this weeks IC. Demand for Oxford instruments constantly evolving range of nanotechnology tools is growing fast. In the first half, adjusted pre-tax profit jumped 24% to £23.1m, which was better than expected, and the high-tech instrument ation specialist is close to hitting internal targets two years early. Once again most of the growth came from China. Sales in Asia grew 23%, easily out-strippingNorth America and Europe. A 200-basis point increase in adjusted operating margin puts Oxford within easy reach of its target of 14% by 2014, and analysts think it could rise to 20% in time. The strongest performance came from nano tools , which posted a 42% rise in profits to £10.4m. Oxfords material characterisation system-used by law enforcement agencies to detect gunshot residue -sold more than expected, and it has not seen any cuts in research funding from governments, either. And the more cyclical industrial unit stillraised profits by 15%, driven by demand for its hand held analysers such as those used to detect heavy metal contamination at the London Olmpic village. Sales of rock core analysers that detect shale oil and gas gushed 80%during the first half, too.
India could be the next big thing , Its pumping cash into the university system and, although its about 8-10 years behind China, offers plenty of opportunity.
Funding for nanotechnology research is growing by 10-20% a year and Oxford Instruments potential to beat both estimates and its own targets justifies a forward PE ratio of 19.

A buy in this weeks IC. Demand for Oxford instruments constantly evolving range of nanotechnology tools is growing fast. In the first half, adjusted pre-tax profit jumped 24% to £23.1m, which was better than expected, and the high-tech instrument ation specialist is close to hitting internal targets two years early. Once again most of the growth came from China. Sales in Asia grew 23%, easily out-strippingNorth America and Europe. A 200-basis point increase in adjusted operating margin puts Oxford within easy reach of its target of 14% by 2014, and analysts think it could rise to 20% in time. The strongest performance came from nano tools , which posted a 42% rise in profits to £10.4m. Oxfords material characterisation system-used by law enforcement agencies to detect gunshot residue -sold more than expected, and it has not seen any cuts in research funding from governments, either. And the more cyclical industrial unit stillraised profits by 15%, driven by demand for its hand held analysers such as those used to detect heavy metal contamination at the London Olmpic village. Sales of rock core analysers that detect shale oil and gas gushed 80%during the first half, too.
India could be the next big thing , Its pumping cash into the university system and, although its about 8-10 years behind China, offers plenty of opportunity.
Funding for nanotechnology research is growing by 10-20% a year and Oxford Instruments potential to beat both estimates and its own targets justifies a forward PE ratio of 19.

:-))

Taken my eye off of this one, But still going up!

Oxford Instruments: Numis increases target price from 1380p to 1825p and maintains an add rating.

Oxford Instruments: JP Morgan takes target price from 1500p to 1750p and leaves its overweight rating unchanged.

Not in this one, but for anyone interested a buy in this weeks Shares mag.

On Thursday, Oxford Instruments PLC (OXIG:LSE) closed at 1,655, 6.90% below its 52-week high of 1,777.65, set on Feb 04, 2013.



As of Mar 22, 2013, the consensus forecast amongst 10 polled investment analysts covering Oxford Instruments plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Aug 15, 2011. The previous consensus forecast advised investors to purchase equity in Oxford Instruments plc.

Oxford Instruments: Investec moves target price from 1420p to 1600p upgrading from sell to hold.

Seems to be taking it's recent customary dip at this time of the year it seems.

Any thoughts Stan of if and when to get back in. :-))

Seem on the drift again ?

Sorry D/C taken my eye off of these recently.

I will keep both eyes peeled stan. Looks like they fell in may last year.

Thanks stan.

Despite the past seasonal dip, it now seems to be bucking that trend with the SP going skywards D/C.

A sell in this weeks Shares mag - Order delays could damage Oxford Instruments.

Scientific technology tools manufacturer Oxford instruments looks vulnerable following cautionary statements from several electronics peers including Spectris and Renishaw. The £896m cap rallied hard in May along with other cyclical stocks as risk appetite returned . But now may be an ideal time to crystallise these gains ahead of next months finals (11 Jun) which could include a cautionary outlook statement for the firms industrial kit business and possibly flag order delays, particularly in Asia.

Final Result
11 Jun 13 Oxford Instruments PLC [OXIG]

Final results: http://www.moneyam.com/action/news/showArticle?id=4611387

Thanks Stan, Post 37 - SM suggested selling - down 7% today.

Yes good call by SM, need to keep an eye on them as the SP has moved around nicely in the past on these DC.

Another fall of over 6% today Stan, all 2013 gains wiped. Side line watcher at the moment.

In IC this week- slow going at Oxford instruments.

Oxford instruments has stacks of long -term potential, but with down-grades likely and growth uncertain, the shares rate no more than a hold.

Black Rock add http://www.moneyam.com/action/news/showArticle?id=4614971

18 Jun Investec 1,490.00 Hold

24 Jun N+1 Singer 1,390.00 Hold

Like just about everything else D/C.. on the slide, will be worth buying at some point though.

Kames Capital go below 4%

Oxford Instruments: Goldman Sachs cuts target price from 2100p to 1850p, while keeping its buy recommendation.

Interim Management Statement

RNS


RNS Number : 1623J

Oxford Instruments PLC

12 July 2013






Release date: 12 July 2013

Oxford Instruments plc

Interim Management Statement

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues an Interim Management Statement which covers the period from 1 April 2013 to date.

As discussed in our Preliminary Statement, the year started slowly with performance in the first two months of the year down against a very strong comparative period in the prior year. However, in the third month of the quarter, orders, sales and profits were much improved compared to each of the first two months and were also ahead of the same period in 2012/13. Average monthly order intake in the quarter was above the monthly average for the last financial year in Asia by 18% but below in North America by 20% and in Europe by 1%.

Our broad spread of geographies and technologies and our strong pipeline of new products continue to underpin the long term prospects for the Group. The Board anticipates that Oxford Instruments will continue to make progress in line with its expectations for the remainder of the financial year and remains focused on achieving its 14 Cubed objectives.

On 11th June 2013 Jennifer Allerton joined the board as an Independent Non-Executive Director.



Save as described in this statement, there has been no significant change in the financial position of the Group in the period.



- Ends -

12 Jul N+1 Singer 1,390.00 Hold

Oxford Instruments reports slow start to the year

Fri, 12 July 2013



Chg %: 9.60%

Date: 16:41


Oxford Instruments, which provides technology for research, had a slow start to the year but sales have picked up, according to a trading update for April 1st to date.

The company said performance in the first two months of the year was down in comparison to a strong prior year. However, sales and profits improved in the third month of the quarter, ahead of the same period last year.

Average monthly order intake in the quarter was higher than the last financial year in Asia by 18% but below in North America by 20% and in Europe by 1.0%.

“Our broad spread of geographies and technologies and our strong pipeline of new products continue to underpin the long term prospects for the group,” the company said.

“The board anticipates that Oxford Instruments will continue to make progress in line with its expectations for the remainder of the financial year and remains focused on achieving its 14 Cubed objectives.”

15 Jul Jefferies... 1,420.00 Hold
15 Jul JP Morgan... 1,750.00 Overweight

Kames Capital go below 3%

Oxford Instruments: Numis downgrades to add with a target price of 1600p

AGM Statement

RNS


RNS Number : 5749N

Oxford Instruments PLC

10 September 2013






Oxford Instruments plc

Chairman's AGM Statement 2013



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, is holding its annual general meeting today in which the Chairman, Nigel Keen will make the following statement:



"In June 2011 we outlined our 14 Cubed objective to achieve a compound annual revenue growth rate of 14% and a return on sales of 14% by the financial year ending March 2014. It was anticipated that this objective would be achieved predominantly through organic growth and continuing internal efficiency improvements, augmented by targeted acquisitions.



The year to March 2013 was the second year of the 14 Cubed plan and we saw compound revenue growth of 15.6% over the two years with return on sales last year of 14.2%.



In the current year, average monthly orders in our Nanotechnology Tools sector are ahead of last year in Asia but are behind in North America and Europe as government agencies in these territories examine their spending on Research and Development. We believe this is particularly true in the USA where the uncertainty caused by budget sequestration has caused orders to be delayed. Asylum Technology, which we acquired in December 2012, is performing well, with results in line with expectations.



Our Industrial Products sector has seen growth in average monthly orders over the previous year in Asia and Europe as global economies begin to recover. North America is still down on the prior year but the trend is improving.



Our third party service business is performing well with the recently acquired Platinum Medical Imaging business continuing to gain traction and delivering the integration benefits.



Outlook

The growth in the order intake rate in Industrial Products and third party Service is encouraging but the slowness in R&D markets in the Western economies means that the year is likely to be more second half weighted than has been seen in recent periods. This will be aided by the continuing recovery in trading conditions in North America

The Capital Group Companies, Inc. go above 16% http://www.moneyam.com/action/news/showArticle?id=4667837

18 Sep Investec 1,515.00 Hold

Black Rock Inc. Go below 18% http://www.moneyam.com/action/news/showArticle?id=4690166

Interim's out tomorrow, wonder how much the foreign exchange rates are affecting these.

Stan, this was in Shares this week -The company designs and supplies some of the very high-technology tools and systems that scientists and researchers need to develop advanced applications. Its business model sees high-tech equipment sold into nanotechnology and industrial markets across the globe, and increasingly to Far East markets keen to expand their technological and scientific research base. This provides a vast and growing installed base from which after-sales parts and service revenues stem, generating highly visible and rising revenues. The company prides itself on turning smart science and innovation into commercially successful products, raising the barriers to entry for new competitors. Research spending cuts in Europe and the US have temporarily slammed the brakes on yet Oxford insists it remains on target to match its ’14 Cubed’ objectives (14% average revenue growth and return on sales, by 2014) (see The Big Debate, pages 36-37). Analysts at Numis point out: ‘Demand for Oxford’s products is being driven by the shift to smaller applications and the ability to analyse and manipulate matter at the atomic level.’ That means increasing nanotechnology research paid for with bigger and bigger budgets, in time. Numis estimates funding levels will increase between 10% and 20% a year going forward, underpinning EPS estimates it has for Oxford of 75.6p next year to March 2015, and 84.2p the year after. That implies a PE of 17.3 falling to 15.

Thanks for that DC, we will know tomorrow.

Half Year report http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11770744
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11770777

Oxford Instruments notes Andor response to bid 12 November 2013 | 15:19pm StockMarketWire.com - Oxford Instruments [LON:OXIG] notes the recent announcement made by Andor Technology plc [LON:AND]. Oxford Instruments has a high regard for the Andor business and its employees and is grateful for the Board of Andor's constructive engagement in the ongoing discussions. Oxford Instruments is developing its business in the Nano-Bio field and believes that the acquisition of Andor has significant industrial and commercial logic. Having substantially completed its due diligence, Oxford Instruments believes that the indicative offer of 500p per share in cash represents an attractive proposal to Andor shareholders. Oxford Instruments looks forward to continuing discussions with the Board of Andor and working with it towards a recommended transaction. At 3:19pm: [LON:OXIG] Oxford Instruments PLC share price was +164p at 1391p Story provided by StockMarketWire.com - See more at: http://www.stockmarketwire.com/article/4704413/Oxford-Instruments-notes-Andor-response-to-bid.html#sthash.r0GAiao3.dpuf



12 Nov N+1 Singer 1,425.00 Hold

Up nearly 9% on the day.

? 16.14% on the day. :-))

Really DC? Only just under 9% on my precent source, Which is not on here unfortunately at the moment.

Have you made 9% on the day Stan, is that what you mean. :-))


Current Share Price Information from OXIG company site.


Current (p) 1425.00

Change (p) 198.00

Change (%) 16.14

Best Bid (p) 1266.00

Best Offer (p) 1980.00

Day Volume 592,770

Chance a be a fine thing DC -): Just looked on their site and yes your right, wow what a rise! Can't remember are you in these at present?

No Stan :-((

You have Andor? well done then, you should be in the money.

:-))

Excellent.

Thought you would have been in this Stan.

Yes I did consider, but think I ducked out because my research indicated that they in past years have dipped at that time of year going forward.

Oxford Instruments’ halfway figures showed a dip in pre-tax profits and revenues as it was hit by curtailed government spending in the US and some low-margin industrial contracts that came to an end. Nevertheless, the dividend is up 10.2% to 3.36p, even though Oxford is not an income stock. Andor investors could consider taking profits, although The Times’ Tempus column says that it would tend to stay in to see what the situation brings.



http://sharecast.com/news/wednesday-tips-round-up-vodafone-andor-technology-bskyb/21289201.html

14 Nov Liberum Capital 1,650.00 Buy

Is it time to invest in Digital Britain? Five top technology shares to rival Twitter

By Marc Shoffman

PUBLISHED: 15:50, 15 November 2013 | UPDATED: 15:50, 15 November 2013


Oxford Instruments


Price-to-earnings ratio: 36.37


Dividend yield: 0.81 per cent


Share price as of 13 November: 1,462.00p

Most recent profits: £22m (31 March 2012)


The first technology business to be spun out from Oxford University over forty years ago, Oxford Instruments creates technology products for research


It was started in the garden shed of Sir Martin Wood in Oxford in 1959 to build superconducting magnets for scientific research. It got backing from Oxford University and listed in 1983.

The company’s best known projects include manufacturing the first commercial MRI scanner.


Mr Mould says: ‘Oxford Instruments’ business model sees high-tech equipment sold into nanotechnology and industrial markets across the globe, and increasingly to Far East markets keen to expand their technological and scientific research base. This provides a vast and growing installed base from which after-sales parts and service revenues stem, generating highly visible and rising revenues.


‘The company prides itself on turning smart science and innovation into commercially successful products, raising the barriers to entry for new competitors. Research spending cuts in Europe and the US have temporarily slammed the brakes on yet Oxford insists it remains on target to match its ’14 Cubed’ objectives of 14 per cent average revenue growth and return on sales, by 2014.'





http://www.dailymail.co.uk/money/investing/article-2505169/Five-UK-technology-stocks-rival-Twitter.html

Update on Possible Offer for Andor Technology plc

RNS


RNS Number : 0991U

Oxford Instruments PLC

27 November 2013






NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION



This is an announcement falling under Rule 2.4 of the City Code on Takeovers and Mergers (the "Code") and does not constitute an announcement of a firm intention to make an offer or to pursue any other transaction under Rule 2.7 of the Code. Accordingly, Andor Technology plc shareholders are advised that there can be no certainty that a formal offer for Andor Technology plc will be forthcoming, even in the event that the pre-conditions in this announcement are satisfied or waived.







27 November 2013





Oxford Instruments plc - Update on Possible Offer for Andor Technology plc



On 12 November 2013, Oxford Instruments plc ("Oxford Instruments" or the "Company") announced that it was in discussions with Andor Technology plc ("Andor") in relation to a possible offer for Andor.

Following the provision of further information including a meeting yesterday between senior management, Oxford Instruments announces that it has now completed its outstanding due diligence and has confirmed to the Board of Andor its proposed offer of 500 pence per share in cash to acquire the entire issued and to be issued share capital of Andor.

The making of any offer remains subject to the following pre-conditions:

i. the unanimous and unqualified recommendation by the Board of Andor in respect of any offer by Oxford Instruments; and

ii. the Directors of Andor giving irrevocable undertakings to accept any offer in respect of all of the Andor shares in which they are interested.

Oxford Instruments reserves the right to waive any or all of the pre-conditions described in this announcement. Even if all of these pre-conditions are satisfied or waived, there can be no certainty that a firm offer will be forthcoming.

Facilities to allow Oxford Instruments to provide certain funds in support of the offer have been negotiated and can be executed at short notice.

Further, Oxford Instruments reserves the right to make an offer on less favourable terms than those set out in this announcement in the event that:

i. Andor announces, declares, pays or makes any dividend or distribution to Andor shareholders at any time, in which case there will be an equivalent reduction in Oxford Instruments' offer price; or

ii. the issued and to be issued share capital of Andor is greater than the 33.2 million shares that has been assumed, such that the pro rata entitlement per Andor share is lower than 500 pence.

Rule 2.6(a) of the Code, requires that Oxford Instruments, by not later than 5.00 p.m. on 10 December2013 (the "relevant deadline"), either announces a firm intention to make an offer for Andor in accordance with Rule 2.7 of the Code or announces that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code.

MIDAS SHARE TIPS UPDATE: Oxford Instruments recommendation sparks another following 774% rise

By Joanne Hart, Financial Mail On Sunday

PUBLISHED: 22:28, 21 December 2013 | UPDATED: 22:28, 21 December 2013

Oxford Instruments has grown from a small, academic business into a highly successful company valued on the stock market at almost £1billion.

Spun out of Oxford University, the stock was first recommended by Midas six years ago, in December 2007. At that time, the shares were 195p and the company was under pressure.


Today, the stock is 1705p and has just agreed a £176 million takeover of Andor Technology, another Midas recommendation (tipped at 5041⁄2p in April 2012, now 525p).





Innovative: The company's research led to the creation of MRI scanners


Oxford Instruments traces its roots back to 1959, when husband and wife team Martin and Audrey Wood developed the world’s first superconducting magnet, which led to the invention of MRI scanners, used in hospitals around the world today.

The Woods founded Oxford Instruments from their garden shed in the city and although the company became known for the brilliance of its scientific team, commercial success proved elusive until Jonathan Flint was appointed chief executive in 2005 with finance director Kevin Boyd joining a year later.

Flint and Boyd have worked hard to blend Oxford Instruments’ scientific expertise with sales and profits growth and the results have been impressive.


Glowing: Oxford Instruments' discoveries are used in sun cream

The company’s technological know-how is used by industries around the world to make products ranging from sun cream to light bulbs to electronic gadgets.


It has even created a tool, called Pulsar, which looks at the chemical composition of meat to see whether it is what it says on the label or something more sinister, such as horsemeat.

Talks are ongoing with supermarket groups and the machine should prove very successful.

Flint is now keen to move into a sector known as nano-bio, which examines tiny particles within, for example, human cells, and uses that knowledge to develop cures for cancer or more resistant crops.


Oxford Instruments provides the tools to foster this research and the acquisition of specialist camera maker Andor will prove helpful in this area.


Andor’s equipment is among the best in the world, but the company has been affected as clients have cut back on research. Oxford Instruments’ 525p-a-share bid is a welcome move for Andor shareholders but it should benefit both companies over the next few years.


Midas verdict: Oxford Instruments shares have risen eight-fold over the past six years, testimony to Flint and Boyd’s drive and vision. Investors could sell up to 30 per cent of their stock and bank the cash, but hang on to their remaining stock as this company should deliver long-term growth.

Shares - Oxford aspires to new heights

Double-digit growth and acquisition synergies to keep shares moving


Shares in Oxford Instruments (OXIG) could fly as high as £21 once analysts settle on new forecasts in the wake of the firm’s recommended takeover of fellow scientific kit maker Andor Technology (AND:AIM).

The promise of a return to double-digit revenue growth should encourage the market to rethink Oxford’s valuation. Operational leverage means progress should be even faster at the profits line and the experts at Deutsche Bank believe operating synergies from the Andor deal will add even greater scope for profits progress as volume orders start to ramp up once more. The investment bank calculates 2% cost savings will be superceded by as much as 10% revenue synergies at the combined group. Deutsche estimates earnings per share (EPS) could jump 23% from 65.2p in 2014 to 80.4p by 2016.

Although the broker’s £21 price target implies a 26 times price/earnings multiple for three years’ time, barriers to entry, good returns on capital and strong earnings momentum could all support such an apparently lofty rating.

Buy

Double-digit revenues and operational gearing should combine to maintain the momentum behind Oxford’s shares and support the bullish consensus view at £16.89.

You must be in this one Stan. :-))

Oxford Instruments PLC (OXIG:LSE) set a new 52-week high during today's trading session when it reached 1,820. Over this period, the share price is up 23.03%.

Afraid not D/C, I called this one very wrong sadly, going great guns isn't it?

:-((

11 Feb JP Morgan... 1,750.00 Overweight

Pre-close Trading Update

RNS


RNS Number : 4651E

Oxford Instruments PLC

10 April 2014






Release Date: 10 April 2014





Pre-close Trading Update





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, is today issuing a trading statement ahead of entering its close period.



As anticipated, there was a strong trading performance in the last quarter. The integration of Andor Technology is proceeding to plan and has aided the results; however this has been offset by the strength of sterling against our main trading currencies. As a result we reiterate the guidance given in our February IMS that we expect performance for the year to be in-line with the prior year.



Oxford Instruments' preliminary results for the year ended 31 March 2014 will be released on Tuesday 10 June.



Ends

Final results Tues 10 June

Final Results

RNS


RNS Number : 2050J

Oxford Instruments PLC

10 June 2014






Release Date: 7am Tuesday 10 June 2014



Oxford Instruments plc

Announcement of Preliminary Results for the year to 31 March 2014



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Preliminary Results for the year to 31 March 2014.



Highlights:



· Orders grew by 2.5% to £342.2 million (2013: £334.0 million)

· Revenue grew by 2.7% to £360.1 million (2013: £350.8 million); 4.3% on a constant currency basis

· Adjusted profit before tax* of £47.1 million (2013: £47.0 million)

· Adjusted operating margin* of 14.0% (2013: 14.1%), in line with 14 Cubed objectives

· Adjusted EPS* up 1.8% at 67.7 pence (2013: 66.5 pence)

· Andor Technology acquisition integrating well and performing ahead of plan

· Investment in R&D, up 11.2% to £27.9 million (2013: £25.1 million)

· Proposed final dividend of 9.04 pence (2013: 8.15 pence), giving a total dividend for the year of 12.4 pence (2013: 11.2 pence)

· Strategy seeks to exploit the convergence of the sciences which will enhance demand for nanotechnology tools

*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in Note 1.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said:



"The Group delivered another successful result, with orders, sales and profits all ahead of the prior year. We are very pleased to welcome Andor to Oxford Instruments and see the acquisition as an important part of the next phase of our growth.



We will continue to focus on developing innovative new products and growing market share in our core areas of physical science. In addition, we will seek to extend our reach into adjacent new markets by applying our tools and technologies to life science research and analysis.



This convergence of the sciences will enhance long term demand for our nanotechnology tools and enable us to reach a new set of customers working in the nano-bio arena."

11 Jun JP Morgan... 1,750.00 Overweight

16 Jun N+1 Singer 1,445.00 Hold

Share tips: 'Why I am backing Oxford Instruments'

Each week we look at a promising mid-cap share. This week: Oxford Instruments, which makes hi-tech equipment for scientific research

Part Of The Atlas Experiment Equipment: How the universe evolved from a liquid

Oxford Instruments only makes around 9pc of its revenue in the UK, making it vulnerable to the strength of the pound Photo: REX FEATURES


By Kyle Caldwell

6:13PM BST 03 Jul 2014




Oxford Instruments, which makes hi-tech equipment for scientific research, has suffered of late from a drop in demand from government-funded projects. But this has not led all investors to rush for the exits.


One fund manager who remains a fan is Chris Murphy, who runs the Aviva Investors UK Equity Income fund. He said that despite a 27pc fall in the share price this year he would remain a long-term holder.


“The firm has an unloved status following pressures of government spending cuts and the effects of a strong pound,” he said. “But having met with the firm last month I came away with the impression of a business turning a corner and a management team with a plan.”


The plan involves focusing on developing new products while keeping an eye on potential acquisitions to expand the business. Oxford Instruments has bought several firms in recent years, the latest being Andor Technology, which it bought for £158m in January.


“The firm’s market-leading products mean that the shares continue to justify premium pricing relative to peers,” Mr Murphy said.


“An improving global outlook should see a return to research funding, while issues such as the horsemeat scandal have led to a dramatic increase in food testing and the need for better technology.”

Interim Management Statement

RNS


RNS Number : 3969M

Oxford Instruments PLC

16 July 2014






Release date: 16 July 2014



Oxford Instruments plc

Interim Management Statement





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues an Interim Management Statement which covers the period from 1 April 2014 to date.

Orders in the first quarter of the year were above the same period last year despite the worsening foreign exchange environment. This was on both a reported and constant currency organic basis.

On a constant currency basis, orders were ahead of the same period last year in our major trading regions of Europe, North America and Asia. Excluding Andor, acquired in January 2014, orders were ahead in North America but lagged in Europe and Asia.

The integration of Andor continues to progress and its performance was slightly ahead of expectations in the first three months of the year.

Our broad spread of geographies and technologies and our strong pipeline of new products continue to underpin the long term prospects for the Group. The Board anticipates that Oxford Instruments will continue to make progress in line with its expectations for the remainder of the financial year.

Save as described in this statement, there has been no significant change in the financial position of the Group in the period.

Beaufort Securities - Oxford Instruments (LOL:OXIG)

Yesterday, Oxford Instruments announced that it expects an enhanced second half owing to better year to date order intake compared to the previous year on a reported and constant currency basis. The company concluded its 14Cubed plan in June and realized a return of 14% on sales and an annually compounded revenue increase of 11% over a period of three years. The successful integration with Andor, acquired in January this year, also helped strengthen the order book in North America and Europe for nanotechnology tools and industrial products. On a separate note, the company announced the retirement of Sir Michael Brady and the appointment of Sir Richard Friend to the board. The stock rose 3.1% in yesterday’s trade.

Our view: The improved order book of Oxford Instruments is well indicative of the robust revenues that could be achieved by the company in this fiscal. Barring a few hiccups from the Asian markets, the company expects to leverage its brand equity and distribution network in the ever expanding market for its products. Oxford Instruments continued efforts to enhance operational efficiencies to focus on convergence of the nano-bio sciences along with strategic acquisitions give the company a good upside potential. We retain a Buy rating for the stock.

Shares - We see scope to surprise on the upside as conditions improve into 2015.

13 Oct Investec 1,405.00 Buy

Interim results Tues 11 Nov

Half Yearly Report

RNS


RNS Number : 6598W

Oxford Instruments PLC

11 November 2014






Release Date: 7am Tuesday 11th November 2014



Oxford Instruments plc

Announcement of Half Year Results for 2014/2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces its Half Year Results for the six months to 30 September 2014.



Highlights:



· First half orders up 19.9% to £201.5 million (2013: £168.0 million); on a constant currency organic basis, orders up 7.4%.

· First half revenue up 7.3% to £178.5 million (2013: £166.3 million); on a constant currency organic basis revenues down 5.9%.

· Adjusted operating profit* of £18.9 million (2013: £22.0 million).

· Adjusted EPS of 20.9 pence (2013: 28.6 pence).

· Andor Technology acquisition integrating well and performing ahead of expectations; integration of RMG and RoentgenAnalytik acquisitions also proceeding to plan.

· Investment in R&D up 41% to £18.3 million with sustained momentum in new product introductions and strong new product pipeline.

· Interim dividend increased by 10.1% to 3.7 pence per share (2013: 3.36 pence).

*Adjusted numbers are stated to give a better understanding of the underlying business performance. Details of adjusting items can be found in Note 2.



Jonathan Flint, Chief Executive of Oxford Instruments plc, said "We will continue to focus on developing innovative new products and growing market share in our core areas of physical science. Our strategy will extend our reach into adjacent new markets by applying our tools and technologies to life science research and analysis, thus extending the reach and reputation of the Oxford Instruments brand worldwide."

----------------------------------------------------------------------------------------------

11 Nov Investec N/A Under Review
11 Nov Numis 1,350.00 Add
11 Nov N+1 Singer 1,350.00 Hold

Trading Statement
RNS
RNS Number : 8176C
Oxford Instruments PLC
22 January 2015



Release date: 7am 22nd January 2015

Oxford Instruments plc Quarter 3 Trading Update

22 January 2015



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues a Quarter 3 Trading Update which covers the period from 1st October 2014 to date.



In the third quarter organic orders and revenues were similar to the same period last year. In addition, Andor the acquisition made in the fourth quarter last year continues to perform well.



Significant orders, both taken in the year and forecast to be taken in Quarter 4, are for delivery to Russia. Recent tightening in the application of trade sanctions and, in particular the cancelling of certain export licences mean we no longer expect to convert theses orders to sales. We now assume that no sales can be made to Russia for the remainder of this year and we are also assuming no sales to Russia next year.



In addition, our forecast of recovery in the Japanese market has not yet occurred. The effects of Russia and Japan, combined with weaker trading in our short lead-time Industrial Analysis business means that, whilst we expect revenues for the second half to be ahead of the same period last year, we believe they will fall short of market expectations. We now anticipate adjusted profit before tax for the current year will be approximately £35 million.



In response to these challenges we are taking action to reduce costs and improve efficiency. Subject to consultation this may result in the closure of some sites and a reduction in headcount. This project aims to produce a cost saving of £6 million in the next financial year. The one off, cash costs of achieving these savings are expected to be in the region of £5 million which will be taken as an exceptional item in the current year.



Whilst it is not possible to predict when the situation in Russia will recover, order intake in Japan is improving. We expect to see the Group grow next year and beyond as we execute on our nanotechnology strategy.

Oxford Instruments (OXIG), down 27.95p, said in response to challenges in Russia and Japan it is taking action to reduce costs and improve efficiency, which could result in some site closures and reduction in headcount. It saw adjusted FY pretax profit at about £35m.

What a slapping!

2 Mar JP Morgan... 1,200.00 Overweight
2 Mar N+1 Singer 765.00 Hold

Acquisition
RNS
RNS Number : 9497L
Oxford Instruments PLC
01 May 2015





Release date: 1 May 2015



Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.





Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).



Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").



The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.



MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:



· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.



Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.



In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).







Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:



Dial: +44 (0)20 3139 4830

PIN: 89662683#







- Ends -

5 May Numis 1,150.00 Buy
5 May Beaufort... N/A Buy
5 May Jefferies... 990.00 Hold
5 May JP Morgan... 1,200.00 Overweight

29 May JP Morgan... 1,200.00 Overweight

Oxford Instruments, a leading provider of high technology tools and systems for industry and research, will announce its results for the year ended 31 March on 9 June.

JV for Oxford Instruments' Omicron business
RNS
RNS Number : 4609O
Oxford Instruments PLC
28 May 2015



For immediate release: 28 May 2015



Oxford Instruments plc

Oxford Instruments enters into Joint Venture with GD Intressenter AB, comprising Omicron Nanotechnology and Scienta Scientific



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces that it has entered into a Joint Venture with GD Intressenter AB of Sweden ("GDI") to create the world's largest player in the highly specialised Ultra High Vacuum Surface Science field. The JV will comprise Oxford Instruments' Omicron Nanotechnology GmbH and associated subsidiaries ("Omicron") and GDI's Scienta Scientific AB and associated subsidiaries ("Scienta").

In consideration for new shares in Scienta, Oxford Instruments has transferred all of its shares in the capital of Omicron to Scienta. Oxford Instruments holds a 47 per cent interest in the share capital of Scienta and GDI holds 53 per cent.

The JV provides excellent opportunities to enhance product development, cut production costs and broaden the product range, while extending market reach and strengthening customer relationships.

The Board of Directors of the JV will include representatives from GDI and Oxford Instruments. The CEO of the new business will be Mr Johan Åman who is based in Uppsala, Sweden. Mr Åman has been CEO of Scienta since 2013 and prior to this he held senior commercial and research positions in Mycronic AB. GDI is backed by a leading Nordic Venture Capital Firm, InnovationsKapital, and other financial investors.



In the twelve months to 31st March 2014, Omicron generated revenue of £28.5 million and a loss before tax of £0.6 million. The gross assets of Omicron at 30th September 2014 were £26.1 million. In the financial year to 31st December 2014, Scienta generated revenue of SEK279 million (approximately £24.6 million) and a profit before tax of SEK25 million (approximately £2.2 million). The gross assets of Scienta at 31st December 2014 were SEK146 million (approximately £12.9 million). Oxford Instruments has provided a term loan of SEK40 million (approximately £3.1 million) to the JV. The transaction will result in no profit or loss on the carrying value of Omicron for Oxford Instruments.



Commenting on the establishment of the JV, Jonathan Flint, Chief Executive of Oxford Instruments, stated:



"This new venture will create the largest player in the exciting field of Surface Science and UHV engineering. Customers will benefit from an enhanced product portfolio and improved service, and the synergies generated by merging the two businesses will provide significant efficiencies and cost savings."



Lars Hagdahl, Chairman of GDI and of the JV, said:

"I am very pleased with the creation of this JV. Going forward together we are a larger and stronger business that will be good for our customers, partners and employees."

Final Results

Watch: Oxford Instruments - Results for the year to 31 March 2015

click here

Lost contact with this but it does move about a bit.

In a downward way, yes. :-))

(ShareCast News) - Oxford Instruments shares should be sold, said the Sunday Times' Inside the City column. The high-tech device maker spun out of Oxford University in 1959 needs to operate right on the bleeding edge of technology, and often depends on acquisitions to stay relevant - but not even that strategy is guaranteed to deliver reliable profits. The company has suffered two profit warnings in the last year, blamed on the sanctions on Russia and China's economic slowdown.
Although OxInst is trading at an attractive discount to rivals on a price-to-earnings basis, the balance sheet is a worry. With the squeeze being felt from weak Japanese demand, slowing industrial sales and lower prices for superconductor parts, management cut 7% of staff last year and recently negotiated better credit terms from lenders. Broker Jefferies has warned that the company's leverage ratios could get close to the higher level its banks have allowed, which any worsening of the Chinese economy, for example, will land OxInst in big trouble.

Market Buzz

Oxford Instruments slumps on Goldman downgrade

Mon, 19 October 2015

Oxford Instruments Quote more



Price: 596.00

Chg: -67.00

Chg %: -10.11%

Date: 17:00



(ShareCast News) - Shares in Oxford Instruments fell sharply after Goldman Sachs downgraded the stock to 'neutral' from 'buy', noting it's trading close to the bank's unchanged 700p price target.
The brokerage said that since being added to the 'buy' list on 26 September 2012, the stock is down 49.4%, compared to the FTSE World Europe up 19.9%.

For full-year 2016, Goldman said it expects adjusted earnings before interest and tax of £43m, compared to Reuters consensus of £45m.

"Weak demand in both the nanotech tools and industrial products business have impacted the shares, and more recently signs of price pressure related to overcapacity in superconducting wire," it said.

Goldman said the group has developed a strong portfolio in the area of nanotech tools. This is a niche market and while it is vulnerable to high short-term volatility, it could offer attractive long-term growth potential and/or strategic attractions for larger instrumentation suppliers, it added.

At 1013 BST, shares in Oxford Instruments were down 8.4% at 607.48p.

Group Financial Director steps down. http://www.moneyam.com/action/news/showArticle?id=5139917

SP down 4% so far.

A Disposal http://www.moneyam.com/action/news/showArticle?id=5159396

Trading statement http://www.moneyam.com/action/news/showArticle?id=5197973

Trading update http://www.moneyam.com/action/news/showArticle?id=5294212

Three tech suppliers thrashing the market

13:00 10/04/2018
Broker Forecast - Peel Hunt issues a broker note on Oxford Instruments PLC
Peel Hunt today upgrades its investment rating on Oxford Instruments PLC (LON:OXIG) to buy (from hold). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

A decent recovery.

12 Apr JP Morgan... N/A Overweight
12 Apr Liberum Capital 1,100.00 Buy
12 Apr Shore Capital 870.00 Hold

09:10 14/06/2018
Broker Forecast - Berenberg issues a broker note on Oxford Instruments PLC
Berenberg today upgrades its investment rating on Oxford Instruments PLC (LON:OXIG) to buy (from hold). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

3 Aug
Liberum Capital
N/A
Buy
3 Aug
Peel Hunt
N/A
Buy